⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
HCWB News
HCW Biologics Inc. Common Stock
HCW Biologics Announces Pricing of $1.5 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules
globenewswire.com
HCWB
HCW Biologics and WY Biotech Announce Closing of First Round of Financing For Newly Formed Joint Venture Trimmune
globenewswire.com
HCWB
HCW Biologics Enters into $4.0 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules
globenewswire.com
HCWB
HCW Biologics Announces Initiation of First-In-Human Clinical Trial to Evaluate HCW9302 in an Autoimmune Disease
globenewswire.com
HCWB
HCW Biologics Reports Third Quarter 2025 Business Highlights and Financial Results
globenewswire.com
HCWB
HCW Biologics Shares the Latest Data for its Second-Generation Immune Checkpoint Inhibitor Presented at the 40th Annual Meeting of the Society for Immunotherapy of Cancer
globenewswire.com
HCWB
HCW Biologics Presents Preclinical Data for TRBC-Based T-Cell Engager Program at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
globenewswire.com
HCWB
HCW Biologics to Participate in the 2025 Maxim Growth Summit
globenewswire.com
HCWB
HCW Biologics’ Scientists to Present Three Posters During the 40th Annual Meeting of the Society for Immunotherapy of Cancer
globenewswire.com
HCWB
HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor “What This Means” Segment About its Proprietary T-Cell Engager Program
globenewswire.com
HCWB